19,136 reports of this reaction
3.5% of all CERTOLIZUMAB PEGOL reports
#2 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #2 most commonly reported adverse reaction for CERTOLIZUMAB PEGOL, manufactured by UCB, Inc.. There are 19,136 FDA adverse event reports linking CERTOLIZUMAB PEGOL to RHEUMATOID ARTHRITIS. This represents approximately 3.5% of all 552,144 adverse event reports for this drug.
Patients taking CERTOLIZUMAB PEGOL who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is moderately reported among CERTOLIZUMAB PEGOL users, representing a notable but not dominant share of adverse events.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for CERTOLIZUMAB PEGOL:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 19,136 FDA reports for CERTOLIZUMAB PEGOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 3.5% of all adverse event reports for CERTOLIZUMAB PEGOL, making it one of the most commonly reported side effect.
If you experience rheumatoid arthritis while taking CERTOLIZUMAB PEGOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.